jdrf therapeutic ventures
TRANSCRIPT
-
7/25/2019 JDRF Therapeutic Ventures
1/10
ACCELERATING LIFE-CHANGING
BREAKTHROUGHS TO CURE, TREAT
AND PREVENT TYPE 1 DIABETES AND
ITS COMPLICATIONS
CONFIDENTIAL
-
7/25/2019 JDRF Therapeutic Ventures
2/10
A NEW STRATEGIC PLAN:
EffectiveAugust 30, 2015
A RESTRUCTURED ORGANIZATION:
Improved efficiency and productivity with lower costs
INCREASE IN LEADERSHIP GIVING:
Dedicated infrastructure to support high-level giving
LAUNCH JDRF THERAPEUTIC VENTURES:
New venture philanthropy approach with donors as active partners
SCALE LEVERAGE OF PUBLIC AND CORPORATE CAPITAL:
Use JDRF Therapeutic Ventures to exploit a proven strength
2
How We Get There
CONFIDENTIAL
-
7/25/2019 JDRF Therapeutic Ventures
3/10
ico
THE OPPORTUNITY
Changing the Course of T1D
PROGRAM THERAPEUTIC GOAL SHORT-TERM (5-7 YEAR) DELIVERABLES
ARTIFICIAL
PANCREAS
Fully-automated system combining continuous glucose
monitor and pump with algorithms to maintain near-normal
glucose levels with minimal user effort
Patient access and reimbursement of predictive low-
glucose suspend and treat-to-range systems; develop, test
and commercialize cell phone controlled, integrated seven-
day micro-patch pump/CGM
ENCAPSULATIONRestoration of insulin independence with replenishable
encapsulated beta cell product without immunosuppression
Clinical proof of concept of stem cell-derived islet & islet
progenitor transplants from multiple companies; multiple
companies within 5-10 years of product availability
GLUCOSE
RESPONSIVE
INSULIN
Change T1D treatment paradigm to once a day injection
resulting in near-normal glucose levels with minimal glucose
measurement, thereby reducing patient burden, short-term
risk, and long-term incidence of complications
Establish clinical proof of concept of at least one new GRI
technological approach; one or more companies in addition
to Merck on path to near- to mid-term commercialization
PREVENTION
Eliminate T1D as a threat to the next generation through
strategies and therapies to intercept and disrupt disease
onset and progression
Development of diabetes prevention vaccines and
therapies, including alteration in intestinal microbiome -
induced immunoregulation; clinical proof of concept withcommercialization in 7-10 years
BETA-CELL
RESTORATION
Return of biological insulin production through restoration
and regeneration of functional beta-cell mass combined with
autoimmunity mediation
Clinical validation of drug repurposing to reverse disease;
Development and proof of principle of gene edited human
stem cell derived islets resistant to immune attack
3CONFIDENTIAL
-
7/25/2019 JDRF Therapeutic Ventures
4/10
THE NEED
Changing the Course of T1D: $375-$625MM
PROGRAM SHORT-TERM (5-7 YEAR) DELIVERABLES INCREMENTAL FINANCIAL NEED
ARTIFICIAL
PANCREAS
Patient access and reimbursement of predictive low-glucose suspend and
treat-to-range systems; develop, test and commercialize cell phone
controlled, integrated seven-day micro-patch pump/CGM$50-$100 MM
ENCAPSULATION
Clinical proof of concept of stem cell-derived islet & islet progenitor
transplants from multiple companies; multiple companies within 5-10 years
of product availability$50-$75 MM
GLUCOSE
RESPONSIVE
INSULIN
Establish clinical proof of concept of at least one new GRI technological
approach; one or more companies in addition to Merck on path to near- to
mid-term commercialization$25-$50 MM
PREVENTION
Development of diabetes prevention vaccines and therapies, including
alteration in intestinal microbiome -induced immunoregulation; clinical
proof of concept with commercialization in 7-10 years$100-$150 MM
BETA-CELL
RESTORATION
Clinical validation of drug repurposing to reverse disease; Development and
proof of principle of gene edited human stem cell derived islets resistant to
immune attack$150-$250 MM
4CONFIDENTIAL
-
7/25/2019 JDRF Therapeutic Ventures
5/10
5
MULTIPLYING THE IMPACT
JDRF Effectively Leverages Donor Funds
100.9 112.2 26.25.0
247.3 267.8
107.2
1,642.0
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
Industry Partners Foundations and Non-
Profit Partners
Foreign Government
Support
US Government
Support
Million
s
Attracted Funding
JDRF Funding
2000
2022
2.5 2.4 4.1 Multiplier
-
7/25/2019 JDRF Therapeutic Ventures
6/10
CF FUND: In 1998, the CFF established a Therapeutics Development Program, apioneering partnership with the biotech community intended to expedite CF research
and the development of drugs to treat CF
VERTEX/KALYDECO:In return for royalty rights, the CFF invested $150 million in VertexPharmaceuticals to develop the drug Kalydeco, effective in patients whose CF is caused
by a specific gene mutation. Following FDA approval of Kalydeco in 2012, CFF sold itsroyalty rights at a profit and reinvested the funds in its research program
JOE ODONNELL: Chairman of the Milestone to a Cure major gifts campaign and
raised over $175 million for the Cystic Fibrosis Foundation. He currently chairs the
Milestones II campaign and plans to raise additional $75 million by the end of 2015
6
THE VEHICLE
Modeled After Cystic Fibrosis Foundation
CONFIDENTIAL
-
7/25/2019 JDRF Therapeutic Ventures
7/10
STRUCTURE: Single member LLC sponsoring a series of closed-end therapeutic funds;maximum expense load of 10% over fund life.
FUNDING:Tax-deductible $500,000 contribution units; returns accrue to fund forreinvestment or distribution to JDRF; Investments may include equity, royalty-based,
low-interest loans with warrant coverage, and/or pilot grants with shared IP or
commercial rights.
OPERATIONS: Separate entity for liability purposes; initially staffed by Steven Griffen,M.D., JDRF VP, Translational Development & Jit Patel, JDRF VP, Research Business
Development; facilities, administration and finance contracted from JDRF.
GOVERNANCE: Five member JDRF Therapeutic Ventures board appointed by JDRF;fund-specific oversight by scientific and device/bio-pharma experts, early stage
investors, and selected donors.
7
THE VEHICLE
JDRF Therapeutic Ventures, LLC
CONFIDENTIAL
-
7/25/2019 JDRF Therapeutic Ventures
8/10
Leverage JDRFs knowledge, network, staff and portfolio, knowledge to
identify most promising opportunities
Create T1D-focused venture philanthropy funds to accelerate development,
commercialization and adoption of therapies
Leverage capital through co-investments with universities, financial and
strategic investors
Utilize and fund JDRF for regulatory, reimbursement, and adoption efforts
Re-invest returns in therapeutic funds
JDRF THERAPEUTIC VENTURES
Change the Course of T1D
8CONFIDENTIAL
-
7/25/2019 JDRF Therapeutic Ventures
9/10
PARTICIPATION:
Advisory board seats; participation in fund investment strategy
COMMUNICATION:
Quarterly progress reports; annual donor briefing; additional access toJDRF staff and researchers
NAMING OPPORTUNITIES:
Fund-specific opportunities for leadership gifts
JDRF THERAPEUTIC VENTURES
Donor Engagement & Recognition
9CONFIDENTIAL
-
7/25/2019 JDRF Therapeutic Ventures
10/10
THANK YOU
CONFIDENTIAL 10